CorMedix Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All 19KA.F news ›CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and... CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference PARSIPPANY,…
Cormedix gets FDA priority review for Rezzayo label expansion
CorMedix (CRMD) stock is in focus on Monday as the FDA grants priority review seeking a label expansion for the company's Rezzayo antifungal drug. Read more here. - CorMedix (CRMD) on Monday announced that the Food and Drug Administration…
CorMedix initiated with an Outperform at Oppenheimer
Oppenheimer analyst Les Sulewski initiated coverage of CorMedix (CRMD) with an Outperform rating and $15 price target Investors appear “overly ... CorMedix initiated with an Outperform at Oppenheimer Oppenheimer analyst Les Sulewski…
RBC Capital Sticks to Their Buy Rating for Cormedix (CRMD)
RBC Capital analyst Leonid Timashev maintained a Buy rating on Cormedix yesterday and set a price target of $14.00. The company’s shares closed yesterday at $8.14. Timashev covers the Healthcare sector, focusing on stocks such as Insmed,…
Analysts Are Bullish on Top Healthcare Stocks: Parabilis Medicines, Inc. (PBLS), Cormedix (CRMD)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Parabilis Medicines, Inc. (PBLS) and Cormedix (CRMD) with bullish sentiments. Parabilis Medicines, Inc. (PBLS) LifeSci Capital analyst Charles…
Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases
The FDA’s acceptance of this supplemental application for Priority Review is an important regulatory milestone for CorMedix, REZZAYO, and for patients who remain at risk for invasive fungal disease,” ... Cormedix Announces FDA Acceptance…
Comparing MediciNova (NASDAQ:MNOV) & CorMedix (NASDAQ:CRMD)
Posted by Mitch Edgeman on Oct 19th, 2026 MediciNova (NASDAQ:MNOV – Get Free Report) and CorMedix (NASDAQ:CRMD – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses…
Head-To-Head Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus CorMedix (NASDAQ:CRMD)
Posted by Tristan Rich on Oct 10th, 2026 CorMedix (NASDAQ:CRMD – Get Free Report) and Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the…
CorMedix Inc (NASDAQ:CRMD) Stock Has Consensus Price Target of $15.00 According to Analysts
Shares of CorMedix Inc (NASDAQ:CRMD – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine research firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
markets.businessinsider.com5
-
themarketsdaily.com4
-
marketbeat.com1
-
seekingalpha.com1
-
stocktitan.net1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.